デフォルト表紙
市場調査レポート
商品コード
1473235

遺伝子編集の提携条件と契約 (2016~2024年)

Gene Editing Collaboration and Licensing Deals 2016-2024

出版日: | 発行: Current Partnering | ページ情報: 英文 250+ Pages | 納期: 即日から翌営業日

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=159.16円
遺伝子編集の提携条件と契約 (2016~2024年)
出版日: 2024年05月01日
発行: Current Partnering
ページ情報: 英文 250+ Pages
納期: 即日から翌営業日
● ご注意事項
本レポートは最新情報反映のため適宜更新し、内容構成変更を行う場合があります。ご検討の際はお問い合わせください。
  • 全表示
  • 概要
  • 目次
概要

当レポートでは、遺伝子編集に関連する昨今 (2016~2024年) の事業協力・ライセンス取引の動向について分析し、全体的な取引件数の推移や、財務面 (支払条件) の傾向、主要企業 による取引形成の動き、契約条件の傾向、遺伝子編集技術別の傾向などを調査すると共に、近年の主要な提携取引の詳細情報を取りまとめてお届けいたします。

目次

エグゼクティブサマリー

第1章 イントロダクション

第2章 遺伝子編集関連の取引形成の傾向

  • イントロダクション
  • 遺伝子編集関連の取引の長期的動向
  • 遺伝子編集関連で最も活発な取引業者
  • 遺伝子編集関連の取引:取引の種類別
  • 遺伝子編集関連の取引:治療分野別
  • 遺伝子編集関連の取引:業界別
  • 遺伝子編集関連の取引:取引条件
    • 遺伝子編集関連の取引:取引総額
    • 遺伝子編集関連の取引:前払い金
    • 遺伝子編集関連の取引:マイルストーン払い
    • 遺伝子編集関連の取引:ロイヤルティ率

第3章 遺伝子編集関連の主な取引

  • イントロダクション
  • 遺伝子編集関連の主要な取引:取引金額ベース

第4章 遺伝子編集関連で最も活発な取引企業

  • イントロダクション
  • 遺伝子編集関連の取引で最も活発な企業
  • 遺伝子編集関連の取引で最も活発な企業:プロファイル

第5章 遺伝子編集関連の契約締結の一覧

  • イントロダクション
  • 遺伝子編集関連の契約締結の一覧

第6章 遺伝子編集関連の取引:技術の種類別

  • 取引一覧
  • 取引一覧:遺伝子編集関連、企業別 (ABC順)
  • 取引一覧:遺伝子編集関連、取引の種類別
  • 取引一覧:遺伝子編集関連、治療分野別
  • 取引の種類の定義
  • Biopharma Research Ltdについて
  • 現在の提携
  • 現在の契約
  • Current Partnering刊行の最近のレポートタイトル
目次
Product Code: CP2150

Gene Editing Collaboration and Licensing Deals provides a comprehensive understanding and unprecedented access to the gene editing deals entered into by the worlds leading biopharma companies.

Fully revised and updated, the report provides details of gene editing deals from 2016 to 2024.

The report provides a detailed understanding and analysis of how and why companies enter gene editing deals. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes.

The report includes collaboration, development, research and licensing deals.

This report contains a comprehensive listing of 354 gene editing deals announced since 2016 including financial terms where available including links to online deal records of actual gene editing partnering deals as disclosed by the deal parties. In addition, where available, records include contract documents as submitted to the Securities Exchange Commission by companies and their partners.

The initial chapters of this report provide an orientation of gene editing dealmaking.

Chapter 1 provides an introduction to the report.

Chapter 2 provides an overview of the trends in gene editing dealmaking since 2016.

Chapter 3 provides an overview of the leading gene editing deals since 2016. Deals are listed by headline value.

Chapter 4 provides a comprehensive listing of the top 25 most active companies in gene editing dealmaking with a brief summary followed by a comprehensive listing of gene editing deals, as well as contract documents available in the public domain.

Chapter 5 provides a comprehensive and detailed review of gene editing deals signed and announced since Jan 2016, where a contract document is available in the public domain.

Chapter 6 provides a comprehensive and detailed review of gene editing partnering deals signed and announced since Jan 2016. The chapter is organized by specific gene editing technology type in focus.

The report also includes numerous table and figures that illustrate the trends and activities in gene editing deal making since 2016.

In addition, a comprehensive deal directory is provided organized by company A-Z, deal type and therapeutic target. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

Key benefits

Gene Editing Collaboration and Licensing Deals provides the reader with the following key benefits:

  • Understand deal trends since 2016
  • Browse gene editing collaboration and licensing deals
  • Benchmark analysis - identify market value of transactions
  • Financials terms - upfront, milestone, royalties
  • Directory of deals by company A-Z, deal type and therapy area
  • Leading deals by value
  • Most active dealmakers
  • Identify assets and deal terms for each transaction
  • Access contract documents - insights into deal structures
  • Due diligence - assess suitability of your proposed deal terms for partner companies
  • Save hundreds of hours of research time

Report scope

  • Gene Editing Collaboration and Licensing Deals is intended to provide the reader with an in-depth understanding of gene editing trends and structure of deals entered into by leading biopharma companies worldwide.

Gene Editing Collaboration and Licensing Deals includes:

  • Trends in gene editing dealmaking in the biopharma industry
  • Directory of gene editing deal records covering pharmaceutical and biotechnology
  • The leading gene editing deals by value
  • Most active gene editing licensing dealmakers
  • Gene Editing Collaboration and Licensing Deals provides comprehensive access to available records for deals, including contract documents where available.

Analyzing contract agreements allows due diligence of:

  • What are the precise rights granted or optioned?
  • What is actually granted by the agreement to the partner company?
  • What exclusivity is granted?
  • What is the payment structure for the deal?
  • How are sales and payments audited?
  • What is the deal term?
  • How are the key terms of the agreement defined?
  • How are IPRs handled and owned?
  • Who is responsible for commercialization?
  • Who is responsible for development, supply, and manufacture?
  • How is confidentiality and publication managed?
  • How are disputes to be resolved?
  • Under what conditions can the deal be terminated?
  • What happens when there is a change of ownership?
  • What sublicensing and subcontracting provisions have been agreed?
  • Which boilerplate clauses does the company insist upon?
  • Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?
  • Which jurisdiction does the company insist upon for agreement law?

Table of Contents

Executive Summary

Chapter 1 - Introduction

Chapter 2 - Trends in gene editing dealmaking

  • 2.1. Introduction
  • 2.2. Gene editing deals over the years
  • 2.3. Most active gene editing dealmakers
  • 2.4. Gene editing deals by deal type
  • 2.5. Gene editing deals by therapy area
  • 2.6. Gene editing deals by industry sector
  • 2.7. Deal terms for gene editing deals
    • 2.7.1 Gene editing deals headline values
    • 2.7.2 Gene editing deal upfront payments
    • 2.7.3 Gene editing deal milestone payments
    • 2.7.4 Gene editing royalty rates

Chapter 3 - Leading gene editing deals

  • 3.1. Introduction
  • 3.2. Top gene editing deals by value

Chapter 4 - Most active gene editing dealmakers

  • 4.1. Introduction
  • 4.2. Most active gene editing dealmakers
  • 4.3. Most active gene editing deals company profiles

Chapter 5 - Gene editing contracts dealmaking directory

  • 5.1. Introduction
  • 5.2. Gene editing contracts dealmaking directory

Chapter 6 - Gene editing dealmaking by technology type

  • Deal directory
  • Deal directory - Gene editing deals by company A-Z
  • Deal directory - Gene editing deals by deal type
  • Deal directory - Gene editing deals by therapy area
  • Deal type definitions
  • About Biopharma Research Ltd
  • Current Partnering
  • Current Agreements
  • Recent report titles from Current Partnering

Table of figures

  • Figure 1: Gene editing deals since 2016
  • Figure 2: Active gene editing dealmaking activity - 2016 - 2024
  • Figure 3: Gene editing deals by deal type since 2016
  • Figure 4: Gene editing deals by therapy area since 2016
  • Figure 5: Gene editing deals by industry sector since 2016
  • Figure 6: Gene editing deals with a headline value
  • Figure 7: Gene editing deals with an upfront value
  • Figure 8: Gene editing deals with a milestone value
  • Figure 9: Gene editing deals with a royalty rate value
  • Figure 10: Top gene editing deals by value since 2016
  • Figure 11: Most active gene editing dealmakers 2016 - 2024
  • Figure 12: Gene editing deals by technology type since 2016